Related Experiment Video

Updated: Mar 22, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K

[The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study]

J Kopecký, O Kubeček

    Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
    |April 16, 2016
    PubMed
    Abstract

    Insights

    Combination therapy with BRAF and MEK inhibitors shows promise for treating metastatic malignant melanoma. This approach may help overcome drug resistance and improve patient outcomes in those with BRAF gene mutations.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Cancer Research

    Context:

    • Metastatic malignant melanoma is a highly fatal cancer.
    • Recent therapeutic advances have improved outcomes, but drug resistance remains a significant challenge.
    • Combination therapy is a strategy to overcome or delay treatment resistance.

    Purpose:

    • To demonstrate the efficacy of combination therapy using BRAF and MEK inhibitors in metastatic malignant melanoma.
    • To suggest the integration of this combination therapy into treatment protocols for eligible patients.

    Summary:

    • A case study highlights successful treatment of metastatic malignant melanoma using a combination of BRAF and MEK inhibitors.
    • This therapeutic approach proved effective in managing the disease.

    Impact:

    • Combination therapy with BRAF and MEK inhibitors can be a viable strategy for treating metastatic malignant melanoma.
    • The findings support the inclusion of this combination therapy in treatment algorithms for patients with BRAF mutations, potentially improving survival rates and managing resistance.

    More Related Videos

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

    Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

    Published on: July 17, 2019

    6.6K
    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

    Published on: September 8, 2021

    3.5K

    Related Concept Videos

    MAPK Signaling Cascades01:07

    MAPK Signaling Cascades

    Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
    9.1K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.4K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.0K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    1.6K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.2K